Both advantages and challenges exist for use of dried blood spots during preclinical drug development. Advantages include small sample volumes coupled with easy shipment and storage. The amount of blood per spot varies (10 to 100 μL), but use of 15 to 20 μL seems...
For pharmaceutical companies, is personalized medicine more of a threat than an opportunity? In addition to the development of new drugs, genetic information can also help target the use of current medications (e.g., Plavix). The use of genetic (or other)...
All medical products pose risks and postmarketing surveillance is critical to expanding the limited evidence base that exists when new drug products are approved. Through initiation of the Sentinel Initiative (May 2008), the Food and Drug Administration (FDA) is...
Ideally, every new drug would represent an unprecedented breakthrough and lead to the creation of a completely novel treatment. This, however, is not the reality of the pharmaceutical industry, or of any other development-based industry. Creating drugs based on...
